Skip to main content

Table 2 Total cost* for patients included in the study with diagnosis of herpes zoster

From: Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the valencian community of Spain

 

TPP perspective**

Societal perspective‡

Direct costsϕ

Total

Mean

SD

%

Total

Mean

SD

%

Primary care visits

11,521.24

88.62

56.14

28.64%

11,521.24

88.62

56.14

23.44%

Primary care emergencies

7,178.42

55.22

86.68

17.84%

7,178.42

55.22

86.68

14.60%

Specialist visits

1,726.48

13.28

41.76

4.29%

1,726.48

13.28

41.76

3.51%

Other professional visits

662.80

5.10

46.72

1.65%

662.80

5.10

46.72

1.35%

Hospitalizations

0

0

0

0

0

0

0

0

Hospital emergencies

2,369.92

18.23

53.62

5.89%

2,369.92

18.23

53.62

4.82%

Diagnostic tests

625.25

4.81

13.92

1.55%

625.25

4.81

13.92

1.27%

Medication

13,443.62

103.41

132.38

33.41%

18,115.26

139.35

138.26

36.85%

Indirect costs#

Absenteeism from work

2,706.18

20.82

137.74

6.73%

6,887.35

52.98

316.86

14.01%

Carers †

0

0

0

0

73.14

0.56

6.41

0.15%

  1. * In 2007 euros.
  2. Other professionals: physiotherapist, nurses and alternative medical practitioners.
  3. † Carers: those persons or relatives who took care of herpes zoster patients.
  4. ** TPP Perspective (Third-Party Payer = Spanish Social Security): public medical visits + diagnostic test + percentage that Spanish National Health System pays for prescriptions.
  5. ‡ Societal perspective: TPP perspective items + percentage that patient pay for prescription + private medical visits + medication not included in the Spanish National System + cost for lost hours of work.
  6. ϕ Direct costs: medical care and medications, and included: 1) the number of medical visits: primary care visits, primary care emergency consultations, specialist visits, other professional visits, hospitalizations, hospital emergencies; 2) medications prescribed and/or consumed and 3) diagnostic tests.
  7. # Indirect costs: productivity losses of patients and/or their carers, calculated from the number of hours of work missed due to herpes zoster.